Helicobacter Pylori Infection, Non Ulcer Dyspepsia, Duodenal Ulcer, Gastric Ulcer, Chronic Active Gastritis, Gastritis
Conditions
Keywords
Helicobacter pylori, Eradication, Sequential therapy, Standard therapy
Brief summary
Eradication rates of Helicobacter pylori (H. pylori) with standard triple therapy are disappointing, and studies from several countries confirm this poor performance. The study aimed to assess the eradication rate of a new sequential treatment regimen compared with conventional triple therapy for the eradication of H. pylori infection.
Detailed description
One thousand and forty-nine dyspeptic patients were studied prospectively. H. pylori-infected patients were randomized to receive 10-day sequential therapy \[rabeprazole (20 mg twice daily) plus amoxicillin (1 g twice daily) for the first 5 days, followed by rabeprazole (20 mg), clarithromycin (500 mg) and tinidazole (500 mg, all twice daily for the remaining 5 days\] or standard 7-day therapy \[corrected\] \[rabeprazole (20 mg), clarithromycin (500 mg) and amoxicillin (1 g), all twice daily\]. H. pylori status was assessed by histology, rapid urease test and 13C-urea breath test at baseline and 6 weeks or more after completion of treatment.
Interventions
Sponsors
Study design
Eligibility
Inclusion criteria
* Presence of active H. pylori infection * Age \>18 years
Exclusion criteria
* Allergy to drug administered * Liver or kidney failure * Pregnancy * Previous treatment for H. pylori infection
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Helicobacter pylori eradication rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Compliance to therapy | — |
Countries
Italy